Main Menu

This technology presents a groundbreaking approach to developing a vaccine for Respiratory Syncytial Virus (RSV), a major cause of severe pediatric respiratory illness. The method involves the creation of a live attenuated RSV vaccine candidate by removing the M2-2 protein, resulting in decreased viral replication. Surprisingly, this modification induces a stronger immune response. The vaccine, derived from LID M2-2 with minor mutations, effectively separates viral replication from immunogenicity.

In this research endeavor, a multifaceted approach has been employed to investigate the intricate roles of CD300 family proteins in immunological processes. Lentiviral transduction of the L929 cell line with mouse and human CD300f genes, followed by puromycin selection, has established cellular models to examine the functions of these receptors. Concurrently, engineered constructs encoding extracellular domains of mouse CD300lb and CD300ld, fused with human IgG1, have been developed for the production of receptor extracellular domain proteins, facilitating studies on protein interactions.

The technology at hand involves a rabbit polyclonal antibody specifically designed for the human Sun1 inner nuclear envelope protein, even though it is directed against the mouse Sun1 inner nuclear membrane protein. Sun1 is known to be an inner nuclear envelope protein, and defects in such proteins can lead to debilitating conditions like Emery-Dreifuss muscular dystrophy and Hutchinson Gilford Progeria Syndrome. Importantly, the antibody serves as a valuable tool for diagnostic and analytical studies concerning cells afflicted with nuclear envelope defects.

This technology involves the discovery and characterization of a novel cell surface antigen uniquely expressed on activated T regulatory (Treg) cells, serving as a receptor for latent transforming growth factor beta-1 (TGF-β1). To explore its role in immune regulation, a specific monoclonal antibody was developed through immunization of hamsters, capable of recognizing this antigen with high specificity.

The technology in focus involves monoclonal antibody CI.11B11.B4.C4, a pioneering biological tool designed to target and bind with high specificity to both isoforms of mouse APOBEC3, mA3 and mA3d5. APOBEC3 proteins play a crucial role in innate immune defense against retroviruses by inducing hypermutation in the viral genome, thereby hindering viral replication and infection.

This technology pertains to the strategic enhancement of HIV neutralizing antibodies through the insertion of specific amino acid substitutions. The substitutions, as described and potentially contributed by biotechnology companies such as Xencor, Genentech, and MedImmune, aim to extend the antibodies' half-life within serum and improve their Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. This innovation has the potential to significantly improve the therapeutic and preventative efficacy of these antibodies against HIV.

The technology involves the development of two specific anti-idiotype monoclonal antibodies, N6-I and N6-2, which target a broadly neutralizing monoclonal antibody (mAb), N6, known for its effectiveness against HIV. These anti-idiotype antibodies are crucial for detecting and monitoring the N6 mAb's quality and quantity in various settings, including in vivo, in vitro, and in clinical trials.

The technology revolves around the discovery of SIRPα (Signal Regulatory Protein alpha) expression on CD8+ T cells as a novel biomarker for assessing T cell functionality during immune exhaustion, a state commonly induced by chronic infections and cancer. The unique expression profile of SIRPα on a subset of functional CD8+ T cells that retain cytotoxic capabilities despite an exhausted phenotype opens new avenues for therapeutic interventions.

The CIS43 antibody represents a cutting-edge advancement in the fight against malaria, a disease caused by Plasmodium parasites and transmitted by mosquitoes. CIS43 targets the junctional epitope of the Plasmodium falciparum circumsporozoite protein, showing promising efficacy in preventing malaria infection in controlled human infection-based studies. The latest developments have focused on generating improved variants of CIS43 with enhanced protective capabilities.

The technology described pertains to the development of bispecific antibodies with enhanced ability to neutralize HIV-1. By structurally designing single chain fragment variable antibodies that join variable regions of multiple broadly neutralizing antibodies (bNAbs) with flexible linkers, the research has yielded a bispecific antibody that targets different epitopes on the HIV-1 envelope. The combination of VRC01—targeting the CD4 binding site—and PGT121—targeting the V3 glycan—has shown promising results.